Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $5.80, but opened at $6.15. Mesoblast shares last traded at $6.55, with a volume of 306,109 shares.
Analyst Ratings Changes
A number of equities analysts have recently commented on the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a report on Friday, January 12th. StockNews.com cut Mesoblast from a "hold" rating to a "sell" rating in a report on Tuesday, April 2nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $13.67.
Check Out Our Latest Analysis on Mesoblast
Mesoblast Stock Performance
The stock has a fifty day moving average of $2.75 and a 200-day moving average of $2.43. The company has a market cap of $717.50 million, a PE ratio of -5.62 and a beta of 3.59.
Hedge Funds Weigh In On Mesoblast
A number of large investors have recently bought and sold shares of the business. BlackRock Inc. boosted its holdings in Mesoblast by 3.8% during the 3rd quarter. BlackRock Inc. now owns 881,883 shares of the company's stock valued at $2,245,000 after acquiring an additional 32,346 shares during the period. State Street Corp bought a new position in shares of Mesoblast in the 1st quarter worth $757,000. Millennium Management LLC bought a new position in shares of Mesoblast in the 4th quarter worth $344,000. Lazari Capital Management Inc. raised its position in shares of Mesoblast by 9.3% in the 3rd quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company's stock worth $116,000 after acquiring an additional 8,000 shares in the last quarter. Finally, Prosperity Wealth Management Inc. acquired a new position in Mesoblast during the 3rd quarter valued at about $79,000. Hedge funds and other institutional investors own 1.43% of the company's stock.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
